Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 5/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.41 |
| ▸ | PARP1 | P09874 | 3/20 | 0.41 |
| ▸ | DHODH | Q02127 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LCLAT1 | Q6UWP7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30203050 | 0.87 | KDM4E (0.40) | KDM4EMAPTALDH1A1TNKSPARP2 | |
| SCHEMBL23368199 | 0.87 | KDM4E (0.40) | KDM4EMAPTALDH1A1TNKSPARP2 | |
| SCHEMBL23355402 | 0.86 | KDM4E (0.41) | KDM4EMAPTALDH1A1TNKSPARP2 | |
| SCHEMBL23355373 | 0.85 | KDM4E (0.45) | KDM4EMAPTALDH1A1SMN1; SMN2DHODH | |
| Trifluoroacetic Acid SCHEMBL23355399 | 0.81 | KDM4E (0.45) | KDM4EMAPTALDH1A1TNKSPARP2 | |
| SCHEMBL23368034 | 0.80 | KDM4E (0.50) | KDM4EMAPTALDH1A1TP53POLB | |
| SCHEMBL23355350 | 0.79 | MAPK14 (0.35) | KDM4EMAPTALDH1A1SMN1; SMN2TNKS | |
| SCHEMBL21612784 | 0.74 | KDM4E (0.47) | KDM4EMAPTALDH1A1SMN1; SMN2TNKS | |
| SCHEMBL23368213 | 0.74 | CYP17A1 (0.42) | KDM4EMAPTALDH1A1SMN1; SMN2DHODH | |
| SCHEMBL30203277 | 0.74 | CYP17A1 (0.42) | KDM4EMAPTALDH1A1SMN1; SMN2DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230025510-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
| EP-3822263-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2021-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025510-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES | ERBB2, EGFR, ERBB3 | KDM4E 2631/4885MAPT 4074/4885ALDH1A1 2836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.